COBRE: NDSU: PROJECT 2: DESIGN, SYNTHESIS AND EVALUATION OF ISOZYME-SPECIFIC

COBRE:NDSU:项目 2:同工酶特异性的设计、合成和评估

基本信息

  • 批准号:
    8360595
  • 负责人:
  • 金额:
    $ 5.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-01 至 2012-09-23
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Histone deacetylases (HDACs) are zinc-dependent hydrolytic enzymes involved in chromatin remodeling and play a critical role in the regulation of gene transcription via deacetylation of histone lysine residues. The small molecule HDAC inhibitor (HDI), suberoylanilide hydroxamic acid (SAHA; also known as Zolinza or Vorinostat) is currently in many clinical trials for cancer chemotherapy and holds great promise for the amelioration of other diseases as well. However, SAHA and other HDIs in development have molecular functionality and broad-spectrum activity with known pharmacokinetic difficulties and will certainly be problematic in the treatment of chronic illnesses. This research will develop new classes of HDIs and offer novel strategies for HDAC inhibition. Key to this project is the design of isozyme-specific HDIs based on competent models of the enzyme. Missing from current efforts in the development of HDIs is the availability of good models of the HDAC Class I isozymes from which to base drug design. This project combines both computational biochemistry and organic synthesis to achieve the goal of isozyme specificity in an HDI. A. Specific Aims Specific Aim 1: Design ixozyme-specific HDAC inhiitors with moderate potency for ideal therapeutic application using computational biochemistry methodologies. By selectively inhibiting individual HDAC isozymes, a better understanding of their role in disease states will be obtained. Currently the most promising HDAC inhibitors emerging from clincal trials have broad-spectrum activity and could pose future clinical issues. Key to this specific aim is the development of competent models for DHAC class I proteins based upon the crystal structure of HDAC8. Highly potent HDACi's have not been beneficial in clinical trials due to upregulation of many genes. We hypotehsize compounds with moderate potency, simliar to SAHA, and with isozyme specificity will be advantageous. Specific Aim 2: Synthesize and evaluate isozyme-specific HDAC inhibitors. A two-pronged approach will be undertaken. First, compounds with hydrophobic fingers to bind deeper in the active site of HDACs will be made based on already obtained preliminary results. Simultaneously, as new models are refinded, HDACi's will be designed to interact specifically with individual isozymes.
这个子项目是利用这些资源的众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GREGORY RICHARD COOK其他文献

GREGORY RICHARD COOK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GREGORY RICHARD COOK', 18)}}的其他基金

COBRE: NDSU: PROJECT 2: DESIGN, SYNTHESIS AND EVALUATION OF ISOZYME-SPECIFIC
COBRE:NDSU:项目 2:同工酶特异性的设计、合成和评估
  • 批准号:
    8167862
  • 财政年份:
    2010
  • 资助金额:
    $ 5.04万
  • 项目类别:
COBRE: NDSU: PROJECT 2: DESIGN, SYNTHESIS AND EVALUATION OF ISOZYME-SPECIFIC
COBRE:NDSU:项目 2:同工酶特异性的设计、合成和评估
  • 批准号:
    7959602
  • 财政年份:
    2009
  • 资助金额:
    $ 5.04万
  • 项目类别:
NEW METHODS FOR THE SYNTHESIS OF UNUSUAL AMINO ACIDS
合成特殊氨基酸的新方法
  • 批准号:
    2727333
  • 财政年份:
    1999
  • 资助金额:
    $ 5.04万
  • 项目类别:
TOTAL SYNTHESIS OF LANKACIDIN C
兰卡西丁 C 的全合成
  • 批准号:
    2102448
  • 财政年份:
    1995
  • 资助金额:
    $ 5.04万
  • 项目类别:
TOTAL SYNTHESIS OF LANKACIDIN C
兰卡西丁 C 的全合成
  • 批准号:
    2102447
  • 财政年份:
    1994
  • 资助金额:
    $ 5.04万
  • 项目类别:

相似国自然基金

帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 批准年份:
    2021
  • 资助金额:
    58.00 万元
  • 项目类别:
    面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
  • 批准号:
    31672538
  • 批准年份:
    2016
  • 资助金额:
    62.0 万元
  • 项目类别:
    面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 批准年份:
    2013
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
  • 批准号:
    81172529
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
  • 批准号:
    81070952
  • 批准年份:
    2010
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
  • 批准号:
    30672361
  • 批准年份:
    2006
  • 资助金额:
    24.0 万元
  • 项目类别:
    面上项目

相似海外基金

Structural biochemistry studies on MAP kinase allosteric binding sites
MAP 激酶变构结合位点的结构生物化学研究
  • 批准号:
    8454542
  • 财政年份:
    2011
  • 资助金额:
    $ 5.04万
  • 项目类别:
Structural biochemistry studies on MAP kinase allosteric binding sites
MAP 激酶变构结合位点的结构生物化学研究
  • 批准号:
    8099975
  • 财政年份:
    2011
  • 资助金额:
    $ 5.04万
  • 项目类别:
Structural biochemistry studies on MAP kinase allosteric binding sites
MAP 激酶变构结合位点的结构生物化学研究
  • 批准号:
    8286268
  • 财政年份:
    2011
  • 资助金额:
    $ 5.04万
  • 项目类别:
BIOCHEMISTRY OF LEUKEMIA VIRUS CORE-BINDING FACTOR
白血病病毒核心结合因子的生物化学
  • 批准号:
    2099053
  • 财政年份:
    1993
  • 资助金额:
    $ 5.04万
  • 项目类别:
BIOCHEMISTRY OF LEUKEMIA VIRUS CORE-BINDING FACTOR
白血病病毒核心结合因子的生物化学
  • 批准号:
    3202487
  • 财政年份:
    1993
  • 资助金额:
    $ 5.04万
  • 项目类别:
Biochemistry of Leukemia Virus Core Binding Factor
白血病病毒核心结合因子的生物化学
  • 批准号:
    7161315
  • 财政年份:
    1993
  • 资助金额:
    $ 5.04万
  • 项目类别:
BIOCHEMISTRY OF LEUKEMIA VIRUS CORE-BINDING FACTOR
白血病病毒核心结合因子的生物化学
  • 批准号:
    2099054
  • 财政年份:
    1993
  • 资助金额:
    $ 5.04万
  • 项目类别:
Biochemistry of Leukemia Virus Core Binding Factor
白血病病毒核心结合因子的生物化学
  • 批准号:
    6829155
  • 财政年份:
    1993
  • 资助金额:
    $ 5.04万
  • 项目类别:
BIOCHEMISTRY OF LEUKEMIA VIRUS CORE BINDING FACTOR
白血病病毒核心结合因子的生物化学
  • 批准号:
    6475801
  • 财政年份:
    1993
  • 资助金额:
    $ 5.04万
  • 项目类别:
Biochemistry of Leukemia Virus Core Binding Factor
白血病病毒核心结合因子的生物化学
  • 批准号:
    8644851
  • 财政年份:
    1993
  • 资助金额:
    $ 5.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了